Medpace (NASDAQ:MEDP) CEO August Troendle Sells 673 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 673 shares of Medpace stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $620.38, for a total transaction of $417,515.74. Following the transaction, the chief executive officer directly owned 544,544 shares in the company, valued at $337,824,206.72. This trade represents a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Medpace Stock Performance

Shares of Medpace stock opened at $611.57 on Friday. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The stock has a market capitalization of $17.07 billion, a price-to-earnings ratio of 35.85, a price-to-earnings-growth ratio of 2.76 and a beta of 1.15. The company has a fifty day moving average of $562.52 and a 200-day moving average of $493.80.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s revenue was up 17.2% compared to the same quarter last year. During the same quarter last year, the company earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Institutional Trading of Medpace

Large investors have recently modified their holdings of the business. BOKF NA lifted its holdings in Medpace by 0.8% in the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after buying an additional 20 shares during the period. Valeo Financial Advisors LLC increased its stake in shares of Medpace by 5.0% during the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after buying an additional 21 shares during the period. UMB Bank n.a. raised its holdings in shares of Medpace by 5.6% during the fourth quarter. UMB Bank n.a. now owns 450 shares of the company’s stock valued at $253,000 after acquiring an additional 24 shares in the last quarter. Schulhoff & Co. Inc. raised its holdings in shares of Medpace by 1.1% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after acquiring an additional 25 shares in the last quarter. Finally, Balefire LLC raised its holdings in shares of Medpace by 6.1% during the first quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after acquiring an additional 26 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

MEDP has been the topic of several analyst reports. BMO Capital Markets lifted their price objective on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and increased their target price for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Robert W. Baird raised their price target on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $535.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Finally, Barclays set a $600.00 price objective on Medpace in a research report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and an average price target of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.